
样式: 排序: IF: - GO 导出 标记为已读
-
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-14 Hinrich Abken
-
Diet-driven microbiome restoration associated with cardiometabolic benefits Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-10 Jordan Hindson
The effects of industrialization on the human gut microbiome have been associated with an increased risk of non-communicable diseases. In a new study published in Cell, researchers have investigated the effect of a non-industrialized-type diet on the gut microbiome and on the risk of chronic diseases. The researchers conducted a randomized controlled feeding trial in 30 healthy Canadian adults. Participants
-
Metabolic diseases in the East Asian populations Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-08 Zhonghan Sun, Yan Zheng
-
A sensory neuron–gastric cancer circuit Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-04 Eleni Kotsiliti
A new study published in Nature explored the role of sensory nerves in gastric cancer. “Cancer cells in extra-cranial solid tumours create an electrical circuit with the sensory nervous system,” says Timothy Wang, corresponding author of the study. Using multiple mouse models of gastric cancer, the researchers showed that sensory nerves expressing calcitonin gene-related peptide (CGRP) created a neural
-
Behavioural interventions increase uptake of CRC screening Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-04 Katrina Ray
A new trial, published in The Lancet, has shown that adding a single sentence with a suggested deadline for return of a faecal immunochemical test (FIT) in the invitation letter reduced the need to issue reminder letters and led to a more timely FIT return as part of a national colorectal cancer (CRC) screening programme. The TEMPO trial was a 2 × 4 factorial, eight-arm, randomized controlled trial
-
International collaborative research to improve gallbladder cancer prevention Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-04-04 Dominique Scherer, Rajiv Kumar, Justo Lorenzo Bermejo
-
Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-24 Bossng Kang
I read with great interest the article by Lee et al. (Lee, B. P. et al. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement. Nat. Rev. Gastroenterol. Hepatol. 21, 626–645 (2024))1. In their Consensus Statement1, the authors are to be commended for their comprehensive framework, which integrates methodologies from alcohol use disorder
-
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’ Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-24 Mack C. Mitchell, Brian P. Lee, Jessica Mellinger, Laura E. Nagy
We thank Kang for their comments on our recent Consensus Statement (Lee, B. P. et al. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement. Nat. Rev. Gastroenterol. Hepatol. 21, 626–645 (2024))1 to incorporate genetic variations into consideration (Kang, B. Incorporating genetic variations in alcohol-associated liver disease trials
-
Cell therapy for liver disorders: past, present and future Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-18 M. Carmen Ortuño-Costela, Massimo Pinzani, Ludovic Vallier
-
EASL Liver Cancer Summit 2025 Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-12 Jordan Hindson
From 20–22 February 2025, Nature Reviews Gastroenterology & Hepatology attended in person the European Association for the Study of the Liver (EASL) Liver Cancer Summit 2025 in Paris, France. The meeting was attended by 720 delegates from 51 countries and there were 238 abstracts submitted, according to the organizers.
-
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-07 Katrina Ray
Vaccines to treat cancer are currently in development, with the potential for personalized treatments targeting specific mutations in various cancer types. A previous phase I trial reported that a personalized RNA neoantigen vaccine was safe and stimulated anti-tumour CD8+ T cells in patients with pancreatic cancer that correlated with delayed recurrence of pancreatic adenocarcinoma (8 of 16, at 1
-
Estimating dietary intake from human stool DNA Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-07 Katrina Ray
Accurately determining dietary and nutrient intake in nutrition research is challenging, and usually reliant on self-reported methods such as dietary questionnaires that can introduce bias. A new study published in Nature Metabolism reports a method for quantifying food-derived DNA in human stool — Metagenomic Estimation of Dietary Intake (MEDI) — by examining faecal metagenomes. This new, semi-quantitative
-
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-07 Christopher D. Byrne, Angelo Armandi, Vanessa Pellegrinelli, Antonio Vidal-Puig, Elisabetta Bugianesi
Correction to: Nature Reviews Gastroenterology & Hepatology https://doi.org/10.1038/s41575-025-01045-z, published online 17 February 2025.
-
ECCO’25 Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-06 Eleni Kotsiliti
In February 2025, Nature Reviews Gastroenterology & Hepatology attended the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO’25) in Berlin, Germany. According to the organizers, 1,776 abstracts were submitted, of which 1,358 were posters and 176 were oral presentations. Compared with previous years, ECCO’25 had the highest attendance, with 8,156 delegates. This year, ECCO focused
-
Developing an adaptive platform trial for evaluation of medical treatments for Crohn’s disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-05 Nurulamin M. Noor, Shellie J. Radford, Babak Choodari-Oskooei, Morris Gordon, Ailsa L. Hart, Trish Hepburn, Ed Juszczak, James O. Lindsay, Nicholas A. Kennedy, Mahesh K. B. Parmar, Vipul Jairath, Gordon W. Moran
-
AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-03 Marietta Iacucci, Yasuharu Maeda, Giovanni Santacroce, Subrata Ghosh
-
A Consensus Statement on establishing causality, therapeutic applications and the use of preclinical models in microbiome research Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-03-03 Amira Metwaly, Aicha Kriaa, Zahra Hassani, Federica Carraturo, Celine Druart, Kaline Arnauts, Paul Wilmes, Jens Walter, Stephan Rosshart, Mahesh S. Desai, Joel Dore, Hervé M. Blottiere, Emmanuelle Maguin, Dirk Haller
-
Reframing obesity and MASLD Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-28
As the burden of obesity and metabolic dysfunction-associated steatotic liver disease increases, the focus is shifting to the wide spectrum of disease, more accurate diagnostic criteria and the systems that influence our health to advance care.
-
Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-26 Norbert Stefan, Giovanni Targher
-
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-26 Jonas Wizenty, Michael Sigal
-
Influence of biological sex in inflammatory bowel diseases Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-17 Diane M. Tshikudi, Charles N. Bernstein, Suresh Mishra, Jean-Eric Ghia, Heather K. Armstrong
-
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-17 Christopher D. Byrne, Angelo Armandi, Vanessa Pellegrinelli, Antonio Vidal-Puig, Elisabetta Bugianesi
-
Neuroimmune interactions influence pancreatic glucagon secretion in fasting mice Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-12 Jordan Hindson
In a new study published in Science, researchers identify a mechanism in mice by which the nervous and immune systems interact to regulate blood glucose levels by controlling pancreatic glucagon secretion. First, they observed that mice with no adaptive lymphocytes and innate lymphoid cells (ILCs) (Rag2−/−Il2rg−/−) had reduced blood glucose and glucagon levels during fasting. But this effect was not
-
Author Correction: Understanding the therapeutic toolkit for inflammatory bowel disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-10 Sophie Vieujean, Vipul Jairath, Laurent Peyrin-Biroulet, Marla Dubinsky, Marietta Iacucci, Fernando Magro, Silvio Danese
Correction to: Nature Reviews Gastroenterology & Hepatology https://doi.org/10.1038/s41575-024-01035-7, published online 31 January 2025.
-
Bridging the gap between science and survival Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-07 Ahsen Ustaoglu
A scientist’s personal journey through breast cancer underscores the urgency for greater empathy in research and healthcare, a patient-centred approach to data dissemination, and more comprehensive, streamlined support for early-career researchers navigating health crises.
-
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-05 Timothy M. Block, Ju-Tao Guo, Fabien Zoulim, Charles M. Rice, Chloe L. Thio, William M. Schneider, Harvey J. Alter, Ira M. Jacobson, Robert G. Gish, Peter D. Block, Mark Sulkowski, Jordan J. Feld, Chari A. Cohen
-
Is precision microbiome medicine just around the corner? Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-04 Silvia Turroni
A study in Nature Medicine developed a new clinical test based on a gut metagenome-derived multispecies biomarker panel for the diagnosis of inflammatory bowel disease, which outperformed faecal calprotectin. Shortly after, a study in Cell identified a health-relevant network-based core microbiome that could substantially advance precision microbiome medicine.
-
MASLD as a non-communicable disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-04 Silvia Sookoian, Carlos J. Pirola, Arun J. Sanyal
Non-communicable diseases represent the primary cause of mortality and morbidity globally, accounting for 74% of all deaths and more than three-quarters of years lived with disability. Here, we argue that metabolic dysfunction-associated steatotic liver disease should be considered a non-communicable disease.
-
Understanding the therapeutic toolkit for inflammatory bowel disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-31 Sophie Vieujean, Vipul Jairath, Laurent Peyrin-Biroulet, Marla Dubinsky, Marietta Iacucci, Fernando Magro, Silvio Danese
-
MASH-induced senescence and liver cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-28 Katrina Ray
Metabolic dysfunction-associated steatohepatitis (MASH) is known to increase the risk of hepatocellular carcinoma (HCC), yet also triggers hepatocyte senescence (a tumour-suppressive cell state). New research shows that the gluconeogenic enzyme fructose-1,6-bisphophatase (FBP1) serves as a key control point in the switch from MASH to HCC. “Since senescence describes a non-dividing cell state associated
-
Coeliac disease: complications and comorbidities Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-28 Jonas F. Ludvigsson, Jialu Yao, Benjamin Lebwohl, Peter H. R. Green, Shuai Yuan, Daniel A. Leffler
-
Rome Foundation Working Team Report on overlap in disorders of gut–brain interaction Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-27 Giovanni Barbara, Imran Aziz, Sarah Ballou, Lin Chang, Alexander C. Ford, Shin Fukudo, Samuel Nurko, Carolina Olano, Miguel Saps, Gregory Sayuk, Kewin T. H. Siah, Lukas Van Oudenhove, Magnus Simrén
-
Preventing the progression of cirrhosis to decompensation and death Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-27 Càndid Villanueva, Dhiraj Tripathi, Jaume Bosch
-
Drug approvals in gastroenterology and hepatology in 2024 Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-13 Eleni Kotsiliti
2024 saw the approvals of several drugs by the FDA and the EMA related to gastroenterology and hepatology. In 2024, the FDA also approved biosimilar products to Stelara (Janssen; ustekinumab, a monoclonal antibody targeting IL-12 and IL-23) for the treatment of moderate to severely active Crohn’s disease and ulcerative colitis, which included Steqeyma (Celltrion), Yesintek (Biocon Biologics), Imuldosa
-
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-01-02 Yasser Fouad, Salma Barakat, Almoutaz Hashim, Hasmik Ghazinyan
Correction to: Nature Reviews Gastroenterology & Hepatology https://doi.org/10.1038/s41575-024-00918-z, published online 18 March 2024.
-
PDAC: advances in tumour microenvironment, microbiome and AI Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-12-20 Minoti Apte
-
Biologic agents for IBD come of age as host–microbe interactions emerge Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-12-13 Leolin Katsidzira, Benjamin Misselwitz
-
Antibiotic-perturbed microbiota and the role of probiotics Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-12-11 Hania Szajewska, Karen P. Scott, Tim de Meij, Sofia K. Forslund-Startceva, Rob Knight, Omry Koren, Paul Little, Bradley C. Johnston, Jan Łukasik, Jotham Suez, Daniel J. Tancredi, Mary Ellen Sanders
-
Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-12-11 Evangelos Triantafyllou, Cathrin L. C. Gudd, Lucia A. Possamai
-
Precision models in hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-12-11 Marina Barcena-Varela, Satdarshan P. Monga, Amaia Lujambio
-
Current and emerging strategies for the prevention of hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-12-09 Yee Hui Yeo, Manal Abdelmalek, Seema Khan, Cynthia A. Moylan, Luz Rodriquez, Augusto Villanueva, Ju Dong Yang
-
The steatotic liver disease burden paradox: unravelling the key role of alcohol Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-12-05 Nikolaj Torp, Mads Israelsen, Aleksander Krag
-
Hepatic vagus nerve relays signals to the brain that can alter food intake Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-29 Rebecca Kelsey
Desynchrony of the mammalian circadian clock has known detrimental metabolic effects, but how synchronous and desynchronous signals are transmitted is unclear. A new study reports that the hepatic vagal afferent nerve (HVAN) transmits signals to the brain that result in changes in food intake and that ablation of the HVAN can prevent aberrant food intake. “We previously reported defects in the molecular
-
Moving towards more personalized approaches in locally advanced and metastatic colorectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-28 Chelsie K. Sievers, Cathy Eng
Colorectal cancer remains a challenging heterogeneous disease with substantial morbidity and mortality. However, progressive advances over the past year have led to marked improvements and overcome challenges previously considered insurmountable. Here, we review key clinical trials in colorectal cancer in 2024, leading to personalized approaches in locally advanced and metastatic disease.
-
Non-canonical metastatic colorectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-21 Eleni Kotsiliti
A new study published in Nature explores the dynamic changes that colorectal cancer (CRC) cells undergo during their transition to the metastatic state by comparing primary tumours with metastases. “Clinically, metastases are less responsive to therapy than primary tumours in the same patients, despite harbouring the same mutations,” says Karuna Ganesh, co-corresponding author of the study. The researchers
-
The ins and outs of tumour resistance Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-22 Michael Attwaters
New research published in Science Translational Medicine identifies an interplay between tumour-intrinsic and tumour-extrinsic factors that drive resistance to treatment in pancreatic ductal adenocarcinoma (PDAC). The findings provide the rationale for combined therapies that target both oncogenic signalling and the tumour microenvironment to overcome PDAC drug resistance. Inhibitors of the RAS–MAPK
-
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-22 Kimberly A. Meerschaert, Isaac M. Chiu
-
High-density lipoprotein lipidome: a neglected source of hepatic lipids Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-18 Gabriele Mocciaro
To define the pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and identify therapeutic options, it is crucial to understand the sources of hepatic fat accumulation. In patients with MASLD, it is estimated that hepatic triglycerides are primarily derived from adipose tissue as free fatty acids (~59%), followed by de novo lipogenesis (~26%) and diet (~15%). However
-
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-18 Valeria Fumagalli, Matteo Iannacone
-
Transforming the landscape of liver cancer detection and care Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-18 Terry Cheuk-Fung Yip, Grace Lai-Hung Wong
-
A new treatment and updated clinical practice guidelines for MASLD Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-11 Elizabeth E. Powell
-
Metabolic health across the ages: how microbiota members support our well-being Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-11 Carolina Tropini
-
Probiotics for preterms: sharing complex decision-making Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-04 Geoffrey A. Preidis, Janet E. Berrington
-
Transport functions of intestinal lymphatic vessels Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-11-04 Patrick Tso, Jeremiah Bernier-Latmani, Tatiana V. Petrova, Min Liu
-
Health disparities in cirrhosis care and liver transplantation Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-10-31 David Goldberg, Julius Wilder, Norah Terrault
-
Gut microbiome: a biomedical revolution Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-10-30 Maria Carmen Collado, Suzanne Devkota, Tarini Shankar Ghosh
To mark the twentieth anniversary of Nature Reviews Gastroenterology & Hepatology, we asked three experts to comment on how the gut microbiome has transformed our understanding of biology and the strengths and limitations of microbiome research today as well as to look ahead at what the next 20 years of microbiome research and clinical applications might look like. In this Viewpoint, Maria Carmen Collado
-
Intestinal tuft cells can act as injury-resistant stem cells Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-10-29 Caroline Barranco
Subsets of human tuft cells retain their proliferative capacity throughout life and can act as a damage-induced pool of regenerative stem cells, report Huang et al. in Nature. Organoids containing all human intestinal cell types were generated by the researchers from a single mature proliferating human tuft cell. Organoids engineered to lack tuft cells did not regenerate after irradiation, unlike those
-
Bitter taste receptors as sensors of gut luminal contents Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-10-28 Catia Sternini, Enrique Rozengurt
-
Alcohol-free and low-strength drinks: friend or foe? Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-10-25 Thomas Marjot, Ashwin Dhanda
Consumption of no and low-alcohol (NoLo) beverages is now commonplace in modern society. However, the debate surrounding the relative risks and benefits of these products is nuanced and evolving, particularly in patients with a history of alcohol use disorder or alcohol-related liver disease. This Comment summarizes the major individual and public health implications of NoLo drinks in order to help
-
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-10-25
Twenty years since the launch of Nature Reviews Gastroenterology & Hepatology, developments in research and clinical practice continue apace. In our anniversary issue, we focus on the past, present and future of gastroenterology and hepatology.